K671

K671 is an experimental small-molecule lipid regulator under investigation for its ability to modulate bone remodeling and promote bone healing, with the goal of serving as a novel anti-osteoporotic therapy. It has been described as a previously unexplored regulator of lipid pathways involved in osteoclast and osteoblast activity, potentially offering a differentiated mechanism relative to existing antiresorptive and anabolic osteoporosis drugs. K671 was reported in connection with Kalytera Therapeutics’ cannabinoid-derived bone disorder program and academic collaborators, but detailed structural information, precise molecular target, pharmacokinetics, and clinical development data have not been publicly disclosed.